Document is current
Any future updates will be listed below
-
Authors
Delabie, Willem
Vandewalle, Vicky
Seghers, Sabrina
De Bleser, Dominique
Vandekerckhove, Philippe
Feys, Hendrik B. https://orcid.org/0000-0003-0052-8852
-
Funding
Funding for this research was provided by:
Belgian Red Cross Flanders (n/a)
- License Information
-
More Information
Article History
Received: 21 February 2025
Accepted: 22 July 2025
First Online: 26 August 2025
Change Date: 29 October 2023
Change Type: Update
Change Details: The original article has been updated to correct the link for ESM5.
Declarations
:
: Material was obtained from consenting healthy voluntary blood and platelet donors from the Belgian Red Cross Flanders Blood Establishment via donation procedures that follow Belgian legislation (‘de bloedwetgeving’). The project was entitled ‘Fundamenteel wetenschappelijk onderzoek op (rest)bloedproducten van vrijwillige bloeddonoren’ approved by the Ethics Institutional Review Board named Universiteit Antwerpen Ethisch Comité with number 18/24/2089, dd 25/06/2018. All human body material was registered in a biobank registered with Federal Agency for Medicines and Health Products accession number (BB190034) approved by the University Hospital Institutional Review board of the University Hospital Leuven (UZ/KU Leuven, S62549). Cells obtained from Lonza (material number PT-5006, batch number 21TL347548) were isolated from donated human tissue after obtaining permission for their use in research applications by informed consent or legal authorization.
: WD, PV and HBF are listed as inventors of pending patent applications for producing platelet lysates. All authors are employed by the Belgian Red Cross-Flanders.
